Lion Biotechnologies announces new manufacturing services agreement with WuXi AppTec

Lion Biotechnologies, Inc., a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte technology (TIL), announced today that it has entered into a new three-year Manufacturing Services Agreement (MSA) and related statements of work with WuXi AppTec, Inc. (WuXi AppTec) to manufacture and perform services related to the manufacture of the Company's autologous cell therapy products.

“During 2017, we intend to expand our clinical program utilising TIL for treatment of solid tumors. The new MSA with WuXi AppTec, and related statements of work, will increase Lion's manufacturing capacity which is a key step in expanding into multiple clinical indications. We will utilise suites with late-stage clinical and commercial capacity dedicated to our TIL program," said Maria Fardis, PhD, MBA, Lion Biotechnologies President and Chief Executive Officer. "We have expanded upon an existing relationship with Wuxi and will be increasing throughput with this new MSA.”

Felix Hsu, Senior Vice President for WuXi AppTec's U.S. Business Unit commented, "We are very pleased that our cell therapy manufacturing, analytical and quality teams will continue to support development and manufacturing of this exciting therapy platform. The fact that our major expansion in late stage clinical and commercial manufacturing facilities could someday facilitate the introduction of effective treatments for solid tumors is exciting.”

Companies